Steven Rubin Buys Shares of Niagen Bioscience, Inc.

Steven Rubin made a move on June 24, 2026, buying 31,746 shares of Niagen Bioscience, Inc. (NasdaqCM: NAGE). The transaction was made at an undisclosed price, but the stock traded near $3.42 on Saturday.

Insider Buying and Selling at Niagen Bioscience, Inc.

Several insiders at Niagen Bioscience, including Steven Rubin, made similar purchases of 31,746 shares each on June 24, 2026. These transactions were not part of any planned trading program, indicating a direct interest in the company's future.

Other Institutional Activity in Niagen Bioscience

BlackRock, Inc. trimmed its holdings in Niagen Bioscience by 204,090 shares, leaving it with 3,871,619 shares valued at approximately $17.1 million. SteelPeak Wealth, LLC opened a new position with 3,373,000 shares worth about $14.9 million. Arrowstreet Capital, Limited Partnership increased its stake by 761,685 shares, bringing its total to 2,378,437 shares valued at around $10.5 million. Vanguard Capital Management LLC also initiated a new position, acquiring 2,149,277 shares worth roughly $9.5 million. Lastly, Tieton Capital Management, LLC added 384,062 shares, bringing its total to 2,029,155 shares, valued at $8.9 million.

Niagen Bioscience, Inc. Stock Up 4.0%

Shares of NasdaqCM:NAGE traded near $3.42 on Saturday. Niagen Bioscience has a market cap of approximately $272.4 million. The stock's P/E ratio stands at 16.3, with a forward P/E of 10.7, and it has a beta of 2.06. Over the past year, the stock has ranged from $3.29 to $14.69. It has a 50-day moving average of $3.99 and a 200-day moving average of $5.83. The company maintains a healthy current ratio of 4.61 and a quick ratio of 3.48, with a debt-to-equity ratio of 3.13.

Analysts Set New Price Targets

On May 11, 2026, HC Wainwright & Co. maintained its buy rating on Niagen Bioscience with a price target of $11.0. Canaccord Genuity also maintained its buy rating, setting a target of $10.0 on May 5, 2026. Overall, the consensus among analysts is a buy rating, with an average price target of $12.6 based on five analyst opinions.

About Niagen Bioscience

Niagen Bioscience, Inc. is a biotechnology company based in Los Angeles, California. It focuses on developing products aimed at promoting healthy aging. The company operates through various segments, including consumer products, ingredients, and pharmaceuticals. Niagen Bioscience offers dietary supplements and proprietary ingredients, such as nicotinamide adenine dinucleotide (NAD+), a crucial coenzyme in cellular metabolism. Founded in 1999, the company is led by CEO Robert N. Fried and employs 117 people.

Bottom Line

Steven Rubin's purchase of Niagen Bioscience shares indicates insider confidence in the company's prospects. Investors often watch insider transactions for signals about a company's future. However, these transactions are backward-looking and may not reflect current conditions. With a solid analyst backing and strategic insider moves, Niagen Bioscience remains a company to watch in the biotechnology sector.